secwatch.observer — SEC 8-K summary
======================================

Issuer:     Humacyte, Inc. (HUMA)
CIK:        0001818382
Form:       8-K
Filed at:   2023-05-12T23:59:59+00:00
Accession:  0001818382-23-000028
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Humacyte Q1 net loss $37M; secures second RMAT for HAV in vascular trauma, plans BLA filing in 2023
--------------------------------------------------------------------------------

- Net loss of $37.0M in Q1 2023 vs $19.8M in Q1 2022; cash & investments $131.7M at March 31, 2023.
- Received second FDA RMAT designation for HAV in urgent arterial repair after extremity vascular trauma.
- Completed enrollment in Phase 3 hemodialysis access trial (240 patients); top-line results expected in 2024.
- Plans to file BLA with FDA later in 2023 for HAV in vascular trauma; V005 trial enrolled 66 patients.
- Subsequent to Q1, secured up to $160M funding arrangement with Oberland Capital to fund operations past potential approval.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1818382/000181838223000028/0001818382-23-000028-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1818382/000181838223000028/huma-20230512.htm
  HTML page:      https://secwatch.observer/filing/0001818382-23-000028

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer